PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
47.13%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
3.87%
D&A growth of 3.87% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
17.23%
Deferred tax of 17.23% while RVPH is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-49.98%
Both cut yoy SBC, with RVPH at -56.99%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
93.54%
Well above RVPH's 125.07% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
48.23%
Lower AP growth vs. RVPH's 101.70%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
21.18%
Lower 'other working capital' growth vs. RVPH's 159.63%. David Dodd would see fewer unexpected short-term demands on cash.
-49.98%
Negative yoy while RVPH is 81.82%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
33.57%
Operating cash flow growth at 75-90% of RVPH's 38.83%. Bill Ackman would recommend further refinements to match competitor’s CFO gains.
-2609.70%
Negative yoy CapEx while RVPH is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2609.70%
We reduce yoy invests while RVPH stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
5.36%
Debt repayment well below RVPH's 52.51%. Michael Burry suspects heavier leverage risk or insufficient cash generation to keep pace.
-80.40%
Negative yoy issuance while RVPH is 4129.39%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.